{"nctId":"NCT00617669","briefTitle":"A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","startDateStruct":{"date":"2008-01"},"conditions":["Prostate Cancer"],"count":1494,"armGroups":[{"label":"Placebo + Docetaxel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Docetaxel","Drug: Placebo"]},{"label":"ZD4054 + Docetaxel","type":"EXPERIMENTAL","interventionNames":["Drug: Docetaxel","Drug: ZD4054"]}],"interventions":[{"name":"Docetaxel","otherNames":["Taxotere®"]},{"name":"ZD4054","otherNames":["Zibotentan"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients who answer TRUE to the following criteria may be eligible to participate in this trial.\n\n* Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has spread to the bone (bone metastasis)\n* Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment\n* Currently receiving treatment with surgical or medical castration\n\nExclusion Criteria:\n\nPatients who answer TRUE to the following ARE NOT eligible to participate in this trial.\n\n* Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial.\n* Suffering from heart failure or had a myocardial infarction within last 6 months\n* A history of epilepsy or seizures","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Median time (in months) from randomisation until death using the Kaplan-Meier method.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"Median time (in months) from randomisation until clinical progression of disease using the Kaplan-Meier method. Progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Skeletal Related Events","description":"Median time (in months) from randomisation until occurrence of a skeletal related event using the Kaplan-Meier method, where skeletal related event is defined as the first occurrence of a pathological fracture, a vertebral compression fracture not related to trauma, prophylactic surgery or radiation for impending fracture or spinal cord compression, or a spinal cord compression.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Prostate-specific Antigen (PSA) Progression","description":"Median time (in months) from randomisation until first PSA value \\>50% higher than baseline of at least 5ng/ml seen in at least 2 consecutive PSA values at least 2 weeks apart using the Kaplan-Meier method.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Progression","description":"Median time (in months) from randomisation until date of first assessment of increased pain using the Kaplan-Meier method, where increased pain event is defined as the first of a patient requiring opiate medication for duration of ≥1 week for pain due to prostate cancer metastasis, pain due to metastasis that has an increase in the worst pain item of the Brief Pain Inventory (BPI) from baseline to a minimum score of 5 with no decrease in analgesic use, or pain due to metastasis requiring radionuclide therapy, radiation therapy or surgery.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Response","description":"Number of patients with a pain response, defined as a decrease in brief pain inventory questionnaire (BPI) of at least 2 points from baseline or a decrease in opiate use of 25% from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life","description":"Median time (in months) from randomisation until deterioration of Health Related Quality of Life using the Kaplan-Meier method, where deterioration is defined as a change from baseline of less than or equal to -6 points in Total FACT-P score maintained for 2 consecutive visits.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PSA Response","description":"PSA response defined as \\>50% decrease in serum PSA values from baseline seen in at least 2 consecutive PSA values at least 2 weeks apart.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"279","spread":null},{"groupId":"OG001","value":"298","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":214,"n":522},"commonTop":["Oedema Peripheral","Alopecia","Diarrhoea","Nausea","Fatigue"]}}}